Previous 10 | Next 10 |
home / stock / clls / clls articles
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously anno...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneeri...
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently anno...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering...
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41&...
Gainers Cellectis S.A. (NASDAQ: CLLS) shares jumped 136% to $2.2799. Cellectis reported strategic collaboration and investment agreements with As...
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company announced a research agreement with AstraZeneca Plc&nbs...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 3...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publicatio...